SFM
MRTX

Signet Financial Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Signet Financial Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,935
Closed -$91K – 888
2018
Q3 		$91K Buy
1,935
+1,575
+438% +$87.7K 0.02% 328
2018
Q2 		$18K Hold
360
– – ﹤0.01% 551
2018
Q1 		$11K Buy
+360
New +$9.99K ﹤0.01% 572

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Signet Financial Management's MRTX Position: Q4 2018 in Review

Signet Financial Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2018, closing a stake of 1,935 shares — an estimated $91K sold.

Signet Financial Management first reported a position in MRTX in Q1 2018 and held it in 3 quarters. The position peaked at $91K in Q3 2018. 112 funds tracked by Wall St. Rank hold MRTX as of Q4 2018.

  • Signet Financial Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Signet Financial Management sold 1,935 Mirati Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $91K.
  • Signet Financial Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Signet Financial Management's Mirati Therapeutics, Inc. Common Stock position peaked at $91K in Q3 2018.
  • 112 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Signet Financial Management's 13F filing for Q4 2018, filed 14 Feb 2019.